Affinity DataKi: 83nMAssay Description:The ability of compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist3 H-SB222200 was assessed by an in vitro ra...More data for this Ligand-Target Pair
Affinity DataKi: 83nMAssay Description:Human NK-3: The ability of compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist 3H-SB222200 was assessed by an...More data for this Ligand-Target Pair
Affinity DataKi: 83nMAssay Description:The ability of compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist3 H-SB222200 was assessed by an in vitro ra...More data for this Ligand-Target Pair
Affinity DataKi: 83nMAssay Description:The affinity of compounds of the invention for the human NK-3 receptor was determined by measuring the ability of compounds of the invention to compe...More data for this Ligand-Target Pair
Affinity DataKi: 100nMpH: 7.4Assay Description:The affinity of compounds of the invention for the human NK-3 receptor was determined by measuring the ability of compounds of the invention to compe...More data for this Ligand-Target Pair
Affinity DataIC50: 148nMAssay Description:Changes in intracellular calcium levels are a recognized indicator of G protein-coupled receptor activity. The efficacy of compounds of the invention...More data for this Ligand-Target Pair
Affinity DataIC50: 285nMAssay Description:Changes in intracellular calcium levels are a recognized indicator of G protein-coupled receptor activity. The efficacy of compounds of the invention...More data for this Ligand-Target Pair